More new rules for trial sponsors and CROs in India

By Gareth Macdonald

- Last updated on GMT

More new rules for trial sponsors and CROs in India

Related tags Clinical trial participants Clinical trial

Drugmakers sponsoring trials in India will need to weigh the potential risks and benefits for the people who take part under new guidelines issued by the CDSCO.

The requirement – set out in a document published this month​ – is designed to bring the trial application process into line with an order issued in October by the Indian Supreme Court in response to a petition filed by study ethics organisation, Swasthya Adhikar Manch​.

Swasthya Adhikar Manch, which campaigns for the rights of clinical trial participants in India, has been lobbying Government officials to tighten up the rules that govern trials, which was acknowledged as a driver for the guidance by CDSCO.

Also under the guidance, trial sponsors are required to say if the drug they are assessing is an innovation and if there is an existing therapeutic option. They must also state if the medicine is for an unmet medical need in India.

The new guidance is the latest in a long list of rule revisions prompted by the Swasthya Adhikar Manch petition – which resulted in 162 studies being halted​ - and other ongoing​ Government investigations of the Indian trial sector.

In July​, for example, CDSCO issued new guidelines on trial design, investigator working practices and on compensation for the families of trial participants who die or are seriously injured during drug research.

Trial approvals up on 2013

To date, efforts to impose stricter regulations on clinical research conducted in Indian do not appear to have made the country less attractive to sponsors.

According to data released by CDSCO in July, 76 clinical studies​ had been approved by the end of May which is nearly three times as many as were given the green light during the equivalent period in 2013.

Whether the number of clinical trials approved this year will top the record 262 studies that were cleared in 2012 remains to be seen.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars